CD47 and lymphoma: We then went on to confirm HX009 binding to selected CD47+ lymphoma cells (Supplement Fig. S1 showing mRNA levels), Raji B- and Jurkat T-lymphoma lines by flow cytometry with the binding dose–response curves shown in Fig. 1D (EC50 21 nM for Raji), in contrast to the minimal binding seen with HX008.